Grant: CIHR Fellowship
McGill University
$90,000.00
Antidepressant effect of d-lysergic acid diethylamide (LSD) microdoses
FY 2018-19
Summary
Mood disorder is a mental disease with an incidence of 5% in Canada, and for which antidepressants currently available are efficacious only in 50% of patients. Depression involves a dysfunction of serotoninergic system in dorsal raphe nucleus (DRN), as well as an hypofunction of the medial prefrontal cortex (PFC). D-lysergic diethylamide acid (LSD) is a hallucinogen that has gained popularity as a recreational drug and recent clinical evidences suggest that it exerts an effect on mood, although this pharmacological and physiological mechanism has not been well explored in animal models. Our hypothesis is that a short-term treatment of LSD could have an antidepressant effect in a model of chronic unpredictable stress (CUS) in mice through the modulation of serotonin and glutamatergic neurotransmissions. Our objectives are : 1)perform behavioral test to evaluate the effect of a short-treatment (7days) of systemic injection of LSD on mice after 6 weeks of CUS, compared with their controls; 2) carry out in vivo electrophysiological recordings to characterize the activity of serotonin and pyramidal neurons in the DRN and in the PFC, respectively, in both stressed and control mice and to test the effect of LSD on these neurons; 3)employ western blotting analysis to investigate whether LSD modulates cortical intracellular signaling proteins which are involved in depression and mood disorders. Adult male and female mice C57BL/6J will be used. We expect that LSD will revert the depressive-like behavior, restore the altered 5-HT and glutamatergic neurotransmissions and normalize the protein levels in the PFC of stressed mice. This study will be useful to understand the pharmacological and molecular mechanism of LSD that could lead to its beneficial use.
Department
Program
CIHR Fellowship
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
397423
Name
De Gregorio Danilo
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Antidepressant effect of d-lysergic acid diethylamide (LSD) microdoses
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Ampa; Behavioural Pharmacology; Drug Discovery; Electrophysiology; Hallucinogens; Lsd; Molecular Biology; Pharmacology; Prefrontal Cortex; Serotonin
Abstract
Mood disorder is a mental disease with an incidence of 5% in Canada, and for which antidepressants currently available are efficacious only in 50% of patients. Depression involves a dysfunction of serotoninergic system in dorsal raphe nucleus (DRN), as well as an hypofunction of the medial prefrontal cortex (PFC). D-lysergic diethylamide acid (LSD) is a hallucinogen that has gained popularity as a recreational drug and recent clinical evidences suggest that it exerts an effect on mood, although this pharmacological and physiological mechanism has not been well explored in animal models. Our hypothesis is that a short-term treatment of LSD could have an antidepressant effect in a model of chronic unpredictable stress (CUS) in mice through the modulation of serotonin and glutamatergic neurotransmissions. Our objectives are : 1)perform behavioral test to evaluate the effect of a short-treatment (7days) of systemic injection of LSD on mice after 6 weeks of CUS, compared with their controls; 2) carry out in vivo electrophysiological recordings to characterize the activity of serotonin and pyramidal neurons in the DRN and in the PFC, respectively, in both stressed and control mice and to test the effect of LSD on these neurons; 3)employ western blotting analysis to investigate whether LSD modulates cortical intracellular signaling proteins which are involved in depression and mood disorders. Adult male and female mice C57BL/6J will be used. We expect that LSD will revert the depressive-like behavior, restore the altered 5-HT and glutamatergic neurotransmissions and normalize the protein levels in the PFC of stressed mice. This study will be useful to understand the pharmacological and molecular mechanism of LSD that could lead to its beneficial use.
Competitiondate
201811
Approvedterm2
2 yrs 0 mth
Pinamesdelim
De Gregorio, Danilo
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~